Avenue Therapeutics, Inc. (ATXI) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Avenue Therapeutics, Inc. (ATXI) Earnings Overview
As of June 21, 2026, Avenue Therapeutics, Inc. (ATXI) reported trailing twelve-month net income of -$2M, reflecting -3.3% year-over-year growth. The company earned $-0.53 per diluted share over the past four quarters, with a net profit margin of -207.2%.
Looking at the long-term picture, ATXI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2025, representing a new all-time high.
Avenue Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PCRX ($9M net income, 1.0% margin), COLL ($75M net income, 8.1% margin), MNKD (-$24M net income, 1.7% margin), ATXI has room to improve margins relative to the peer group. Compare ATXI vs PCRX →
ATXI Earnings vs Peers
Earnings metrics vs comparable public companies
ATXI Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$3M | +75.0% | -$3M | $-0.93 | -207.2% | -234.0% |
| 2024 | -$12M | -12.3% | -$11M | $-0.90 | - | - |
| 2023 | -$10M | -192.1% | -$15M | $-73.48 | - | - |
| 2022 | -$4M | +4.8% | -$8M | $-121.91 | - | - |
| 2021 | -$4M | +27.6% | -$4M | $-3.29 | - | - |
| 2020 | -$5M | +80.1% | -$5M | $-4.65 | - | - |
| 2019 | -$26M | -20.2% | -$26M | $-24.38 | - | - |
| 2018 | -$22M | -75.8% | -$22M | $-31.17 | - | - |
| 2017 | -$12M | -285.8% | -$11M | $-27.71 | - | - |
| 2016 | -$3M | +39.2% | -$2M | $-5.39 | - | - |
| 2015 | -$5M | - | -$5M | $-9.40 | - | - |
Download Data
Export ATXI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ATXI — Frequently Asked Questions
Quick answers to the most common questions about buying ATXI stock.
What is ATXI earnings per share (EPS)?
ATXI trailing twelve-month (TTM) diluted EPS is $-0.53, reflecting -3.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Avenue Therapeutics, Inc.'s net income?
Avenue Therapeutics, Inc. (ATXI) trailing twelve-month net income is $-2M as of 2025. Earnings declined -3.3% year-over-year.
Is ATXI profitable?
ATXI is not currently profitable on a TTM basis, reporting a net loss of $-2M. Net margin is -207.2%. Investors should monitor for a return to profitability.
What is ATXI's earnings growth rate?
ATXI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are ATXI's profit margins?
Avenue Therapeutics, Inc. net profit margin is -207.2%, operating margin is -234.0%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -157.8%.
Is ATXI growing earnings?
ATXI earnings growth is slowing. Current YoY EPS growth of -3.3% trails the 5-year CAGR of N/A. TTM net income is $-2M.
What was ATXI's best earnings year?
Avenue Therapeutics, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2025. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were ATXI's earnings last quarter?
ATXI's most recent reported quarter was Q1 2026. Net income was $-695000.00 with diluted EPS of $-0.21. For a full breakdown of all quarters, see the quarterly earnings table on this page.